Fotemustine (FTM) is a common treatment option for glioblastoma patients refractory to temozolomide (TMZ). Although elderly patients represent a large component of glioblastoma population, the feasibility and the efficacy of second-line FTM are not available in those patients.We retrospectively analyzed the records of glioblastoma patients older than 65 years, receiving FTM at a dose of 70-100 mg/m2 of FTM every week for 3 consecutive weeks (induction phase) and then every 3 weeks (70-100 mg/m2), as second-line treatment.Between January 2004 and December 2011, 65 glioblastoma patients (median age, 70 years; range, 65-79 years) were eligible for this analysis. Sixty-five patients received a total of 364 FTM cycles, with a median of 4 cycles for each patient. After induction, we observed 1 complete response (1.5 %), 12 partial responses (18.5 %), 18 stable diseases (27.7 %), and 34 patients' progressions (47.7 %). Disease control rate was 43.1 %. Median survival from the beginning of FTM therapy was 7.1 months, while the median progression-free survival was 4.2 months, and the 6-months progression free survival rate was 35.4 %. The most relevant grade 3-4 toxicity events were thrombocytopenia (15.3 %) and neutropenia (9.2 %). In the univariate and multivariate analysis, time from radiotherapy to FTM, number of TMZ and FTM cycles and disease control resulted independent prognostic factors.This study showed that FTM is a valuable therapeutic option for elderly glioblastoma patients, with a safe toxicity profile

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma / Matteo Santoni;Silvia Scoccianti;Ivan Lolli;Maria Grazia Fabrini;Giovanni Silvano;Beatrice Detti;Franco Perrone;Giuseppina Savio;Roberto Iacovelli;Luciano Burattini;Rossana Berardi;Stefano Cascinu. - In: JOURNAL OF NEURO-ONCOLOGY. - ISSN 0167-594X. - STAMPA. - 113:(2013), pp. 397-401. [10.1007/s11060-013-1125-3]

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma

SCOCCIANTI, SILVIA;
2013

Abstract

Fotemustine (FTM) is a common treatment option for glioblastoma patients refractory to temozolomide (TMZ). Although elderly patients represent a large component of glioblastoma population, the feasibility and the efficacy of second-line FTM are not available in those patients.We retrospectively analyzed the records of glioblastoma patients older than 65 years, receiving FTM at a dose of 70-100 mg/m2 of FTM every week for 3 consecutive weeks (induction phase) and then every 3 weeks (70-100 mg/m2), as second-line treatment.Between January 2004 and December 2011, 65 glioblastoma patients (median age, 70 years; range, 65-79 years) were eligible for this analysis. Sixty-five patients received a total of 364 FTM cycles, with a median of 4 cycles for each patient. After induction, we observed 1 complete response (1.5 %), 12 partial responses (18.5 %), 18 stable diseases (27.7 %), and 34 patients' progressions (47.7 %). Disease control rate was 43.1 %. Median survival from the beginning of FTM therapy was 7.1 months, while the median progression-free survival was 4.2 months, and the 6-months progression free survival rate was 35.4 %. The most relevant grade 3-4 toxicity events were thrombocytopenia (15.3 %) and neutropenia (9.2 %). In the univariate and multivariate analysis, time from radiotherapy to FTM, number of TMZ and FTM cycles and disease control resulted independent prognostic factors.This study showed that FTM is a valuable therapeutic option for elderly glioblastoma patients, with a safe toxicity profile
2013
113
397
401
Matteo Santoni;Silvia Scoccianti;Ivan Lolli;Maria Grazia Fabrini;Giovanni Silvano;Beatrice Detti;Franco Perrone;Giuseppina Savio;Roberto Iacovelli;Luciano Burattini;Rossana Berardi;Stefano Cascinu
File in questo prodotto:
File Dimensione Formato  
2013 Fotemustine in elderly pts Santoni JNO.pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 184.62 kB
Formato Adobe PDF
184.62 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/822538
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 10
social impact